Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice.

Sacco A, Bruno A, Contursi A, Dovizio M, Tacconelli S, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Fullone R, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Patrono C, FitzGerald GA, Yu Y, Patrignani P.

J Pharmacol Exp Ther. 2019 Sep;370(3):416-426. doi: 10.1124/jpet.119.259382. Epub 2019 Jun 27.

PMID:
31248980
2.

miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction.

Saul MJ, Baumann I, Bruno A, Emmerich AC, Wellstein J, Ottinger SM, Contursi A, Dovizio M, Donnini S, Tacconelli S, Raouf J, Idborg H, Stein S, Korotkova M, Savai R, Terzuoli E, Sala G, Seeger W, Jakobsson PJ, Patrignani P, Suess B, Steinhilber D.

FASEB J. 2019 Jun;33(6):6933-6947. doi: 10.1096/fj.201802547R. Epub 2019 Mar 28.

PMID:
30922080
3.

Antithrombotic Agents and Cancer.

Bruno A, Dovizio M, Tacconelli S, Contursi A, Ballerini P, Patrignani P.

Cancers (Basel). 2018 Jul 31;10(8). pii: E253. doi: 10.3390/cancers10080253. Review.

4.

Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for Cardiovascular Disease.

Tacconelli S, Dovizio M, Di Francesco L, Meneguzzi A, D'Agostino I, Evangelista V, Manarini S, Capone ML, Grossi L, Porreca E, Di Febbo C, Bruno A, Ballerini P, Levantesi G, Fava C, Minuz P, Patrignani P.

Clin Pharmacol Ther. 2018 Jul;104(1):111-119. doi: 10.1002/cpt.1075. Epub 2018 Apr 19.

PMID:
29574792
5.

P2Y12 Receptors in Tumorigenesis and Metastasis.

Ballerini P, Dovizio M, Bruno A, Tacconelli S, Patrignani P.

Front Pharmacol. 2018 Feb 2;9:66. doi: 10.3389/fphar.2018.00066. eCollection 2018. Review.

6.

Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.

Tacconelli S, Bruno A, Grande R, Ballerini P, Patrignani P.

Expert Opin Drug Saf. 2017 Jul;16(7):791-807. doi: 10.1080/14740338.2017.1338272. Epub 2017 Jun 8. Review.

PMID:
28569569
7.

Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer.

Patrignani P, Sacco A, Sostres C, Bruno A, Dovizio M, Piazuelo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, Tacconelli S, Patrono C, Lanas A.

Clin Pharmacol Ther. 2017 Jul;102(1):52-61. doi: 10.1002/cpt.639. Epub 2017 Apr 4.

PMID:
28139830
8.

Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells.

Di Francesco L, Dovizio M, Trenti A, Marcantoni E, Moore A, O'Gaora P, McCarthy C, Tacconelli S, Bruno A, Alberti S, Gizzo S, Nardelli GB, Orso G, Belton O, Trevisi L, Dixon DA, Patrignani P.

Br J Pharmacol. 2015 Sep;172(18):4575-4587. doi: 10.1111/bph.13241. Epub 2015 Aug 3.

9.

Inside epoxyeicosatrienoic acids and cardiovascular disease.

Tacconelli S, Patrignani P.

Front Pharmacol. 2014 Nov 10;5:239. doi: 10.3389/fphar.2014.00239. eCollection 2014. Review.

10.

Gut microbiota, host gene expression, and aging.

Patrignani P, Tacconelli S, Bruno A.

J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S28-31. doi: 10.1097/MCG.0000000000000229. Review.

PMID:
25291121
11.

Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.

Patrignani P, Tacconelli S, Piazuelo E, Di Francesco L, Dovizio M, Sostres C, Marcantoni E, Guillem-Llobat P, Del Boccio P, Zucchelli M, Patrono C, Lanas A.

J Thromb Haemost. 2014 Aug;12(8):1320-30. doi: 10.1111/jth.12637. Epub 2014 Jul 18.

12.

Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.

Bruno A, Tacconelli S, Patrignani P.

Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):56-63. doi: 10.1111/bcpt.12117. Epub 2013 Sep 3. Review.

13.

Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.

Maenthaisong R, Tacconelli S, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P, Suthisisang C.

Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):403-17.

PMID:
23755755
14.

Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.

Vitale P, Tacconelli S, Perrone MG, Malerba P, Simone L, Scilimati A, Lavecchia A, Dovizio M, Marcantoni E, Bruno A, Patrignani P.

J Med Chem. 2013 Jun 13;56(11):4277-99. doi: 10.1021/jm301905a. Epub 2013 May 16.

PMID:
23651359
15.

Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract.

Bruno A, Dovizio M, Tacconelli S, Patrignani P.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):e1-e13. doi: 10.1016/j.bpg.2012.10.001. Review.

PMID:
23199511
16.

Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.

Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P.

Recent Results Cancer Res. 2013;191:67-93. doi: 10.1007/978-3-642-30331-9_4. Review.

PMID:
22893200
17.

Mode of action of aspirin as a chemopreventive agent.

Dovizio M, Bruno A, Tacconelli S, Patrignani P.

Recent Results Cancer Res. 2013;191:39-65. doi: 10.1007/978-3-642-30331-9_3. Review.

PMID:
22893199
18.

Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study.

Cesari M, Kritchevsky SB, Nicklas B, Kanaya AM, Patrignani P, Tacconelli S, Tranah GJ, Tognoni G, Harris TB, Incalzi RA, Newman AB, Pahor M; Health ABC study.

J Gerontol A Biol Sci Med Sci. 2012 Jun;67(6):671-6. doi: 10.1093/gerona/glr246. Epub 2012 Mar 1.

19.

Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression.

Marcantoni E, Di Francesco L, Totani L, Piccoli A, Evangelista V, Tacconelli S, Patrignani P.

Prostaglandins Other Lipid Mediat. 2012 Aug;98(3-4):122-8. doi: 10.1016/j.prostaglandins.2012.01.006. Epub 2012 Feb 6.

PMID:
22330859
20.

Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.

Dovizio M, Tacconelli S, Ricciotti E, Bruno A, Maier TJ, Anzellotti P, Di Francesco L, Sala P, Signoroni S, Bertario L, Dixon DA, Lawson JA, Steinhilber D, FitzGerald GA, Patrignani P.

J Pharmacol Exp Ther. 2012 Apr;341(1):242-50. doi: 10.1124/jpet.111.190785. Epub 2012 Jan 19.

21.

Mechanistic and pharmacological issues of aspirin as an anticancer agent.

Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P.

Pharmaceuticals (Basel). 2012 Dec 5;5(12):1346-71. doi: 10.3390/ph5121346.

22.

Managing the adverse effects of nonsteroidal anti-inflammatory drugs.

Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A.

Expert Rev Clin Pharmacol. 2011 Sep;4(5):605-21. doi: 10.1586/ecp.11.36. Review.

PMID:
22114888
23.

Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.

Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J.

J Clin Invest. 2011 Nov;121(11):4462-76. doi: 10.1172/JCI59291. Epub 2011 Oct 17.

24.

Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.

Biava M, Porretta GC, Poce G, Battilocchio C, Botta M, Manetti F, Rovini M, Cappelli A, Sautebin L, Rossi A, Pergola C, Ghelardini C, Galeotti N, Makovec F, Giordani A, Anzellotti P, Tacconelli S, Patrignani P, Anzini M.

Curr Med Chem. 2011;18(10):1540-54. Review.

PMID:
21428878
25.

Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.

Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P.

Arthritis Rheum. 2011 Mar;63(3):850-9. doi: 10.1002/art.30175.

26.

Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation.

Tacconelli S, Capone ML, Patrignani P.

Methods Mol Biol. 2010;644:165-78. doi: 10.1007/978-1-59745-364-6_14.

PMID:
20645173
27.

NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population.

Capone ML, Tacconelli S, Rodriguez LG, Patrignani P.

Pharmacol Rep. 2010 May-Jun;62(3):530-5. Review.

28.

Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding.

Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA.

Arthritis Rheum. 2010 Jun;62(6):1592-601. doi: 10.1002/art.27412.

29.

Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century.

Patrignani P, Tacconelli S, Bruno A.

Front Pharmacol. 2010 May 6;1:2. doi: 10.3389/fphar.2010.00002. eCollection 2010. No abstract available.

30.

Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro.

Bruno A, Di Francesco L, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di Francesco A, Tacconelli S, Capone ML, Patrignani P.

Biochem Pharmacol. 2010 Apr 1;79(7):974-81. doi: 10.1016/j.bcp.2009.11.011. Epub 2009 Nov 27.

PMID:
19925781
31.

Risk management profile of etoricoxib: an example of personalized medicine.

Patrignani P, Tacconelli S, Capone ML.

Ther Clin Risk Manag. 2008 Oct;4(5):983-97.

32.

Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population.

García Rodríguez LA, Tacconelli S, Patrignani P.

J Am Coll Cardiol. 2008 Nov 11;52(20):1628-36. doi: 10.1016/j.jacc.2008.08.041.

33.

Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study.

Patrignani P, Di Febbo C, Tacconelli S, Douville K, Guglielmi MD, Horvath RJ, Ding M, Sierra K, Stitham J, Gleim S, Baccante G, Moretta V, Di Francesco L, Capone ML, Porreca E, Hwa J.

Pharmacogenet Genomics. 2008 Jul;18(7):611-20. doi: 10.1097/FPC.0b013e328301a774.

PMID:
18551041
34.

Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease.

Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC.

Hypertension. 2008 May;51(5):1379-85. doi: 10.1161/HYPERTENSIONAHA.107.105395. Epub 2008 Mar 31.

35.

NSAIDs and cardiovascular disease.

Patrignani P, Capone ML, Tacconelli S.

Heart. 2008 Apr;94(4):395-7. doi: 10.1136/hrt.2007.136002. No abstract available.

PMID:
18347364
36.

Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs.

Capone ML, Tacconelli S, Di Francesco L, Petrelli M, Patrignani P.

Expert Opin Drug Saf. 2008 Jan;7(1):29-42. doi: 10.1517/14740338.7.1.29 . Review.

PMID:
18171312
37.

Human pharmacology of naproxen sodium.

Capone ML, Tacconelli S, Sciulli MG, Anzellotti P, Di Francesco L, Merciaro G, Di Gregorio P, Patrignani P.

J Pharmacol Exp Ther. 2007 Aug;322(2):453-60. Epub 2007 May 1.

PMID:
17473175
38.

Pharmacodynamic of cyclooxygenase inhibitors in humans.

Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94. Epub 2006 Jul 3. Review.

PMID:
17164136
39.

Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.

Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P.

Clin Pharmacol Ther. 2006 Sep;80(3):264-74.

PMID:
16952493
40.

Clinical pharmacology of etoricoxib.

Capone ML, Tacconelli S, Patrignani P.

Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):269-82. Review.

PMID:
16922642
41.

Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.

Sciulli MG, Renda G, Capone ML, Tacconelli S, Ricciotti E, Manarini S, Evangelista V, Rebuzzi A, Patrignani P.

Clin Pharmacol Ther. 2006 Aug;80(2):115-25. Epub 2006 Jul 3.

PMID:
16890573
42.

De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.

Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, Tacconelli S, Sacchetti A, D'Angelo S, Scilimati A, Sciulli MG, Patrignani P.

Circ Res. 2006 Mar 17;98(5):593-5. Epub 2006 Feb 16.

PMID:
16484611
43.

The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.

Sciulli MG, Capone ML, Tacconelli S, Patrignani P.

Pharmacol Rep. 2005;57 Suppl:66-85. Review.

PMID:
16415488
44.

Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo.

Patrignani P, Di Febbo C, Tacconelli S, Moretta V, Baccante G, Sciulli MG, Ricciotti E, Capone ML, Antonucci I, Guglielmi MD, Stuppia L, Porreca E.

Blood. 2006 May 1;107(9):3572-4. Epub 2006 Jan 5.

45.

Isoprostanes and other markers of peroxidation in atherosclerosis.

Patrignani P, Tacconelli S.

Biomarkers. 2005 Nov;10 Suppl 1:S24-9. Review.

PMID:
16298908
46.

New insights into COX-2 biology and inhibition.

Patrignani P, Tacconelli S, Sciulli MG, Capone ML.

Brain Res Brain Res Rev. 2005 Apr;48(2):352-9. Review.

PMID:
15850674
47.

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.

Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P.

J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. Review.

48.

Platelet activation in patients with colorectal cancer.

Sciulli MG, Filabozzi P, Tacconelli S, Padovano R, Ricciotti E, Capone ML, Grana M, Carnevale V, Patrignani P.

Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):79-83.

PMID:
15626589
49.

Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.

Di Nunno L, Vitale P, Scilimati A, Tacconelli S, Patrignani P.

J Med Chem. 2004 Sep 23;47(20):4881-90.

PMID:
15369392
50.

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.

Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P.

Circulation. 2004 Mar 30;109(12):1468-71. Epub 2004 Mar 22.

PMID:
15037526

Supplemental Content

Loading ...
Support Center